APUS apimedsus.com Net earnings per share for the last 12 months

Apimeds Pharmaceuticals (APUS) strictly adheres to biochemical waste disposal regulations during the development of neurological drugs. Rolling year earnings per share demonstrate the business's financial stability, where -36.44 is recorded as the baseline value. The company is investing in renewable energy for its offices while simultaneously optimizing specialized raw material supply chains through the diversification of contract laboratories.

APUS Apimeds Pharmaceuticals Earnings per share for the trailing year (05/10/2025 - 11/14/2026)

Apimeds Pharmaceuticals, Inc. - analytical breakdowns and key metrics (APUS)

- stock price and consensus target price:

Stock Price Apimeds|APUS - Average Forecast Price

- market capitalization data:

Market Valuation Apimeds Pharmaceuticals US|APUS - Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Apimeds Pharmaceuticals|APUS - Accounting Value of Company|Market Value to Book Value Ratio apimedsus.com|APUS - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

APUS - Net Profit|Expected Profit Apimeds Pharmaceuticals|APUS - Market Cap to Net Income|Forward P/E Multiple Apimeds|APUS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apimeds Pharmaceuticals US|APUS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Apimeds Pharmaceuticals|APUS - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth apimedsus.com|APUS - Earnings per share growth this year|Net earnings per share growth forecast for next year Apimeds Pharmaceuticals

- issuer revenue and sales details:

APUS - Company Gross Revenue|Company Future Sales Volume Apimeds|APUS - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Apimeds Pharmaceuticals US

Basic company analysis:apimedsus.com (APUS)

The development of unique bee venom-based drugs and clinical trials in the US and Asia form the operational foundation of Apimeds Pharmaceuticals (APUS). These results translate into net income distributed per common share on a rolling year basis. This metric measures the actual efficiency of capitalization, excluding the impact of the total issuance volume. It allows for the differentiation of sustainable margins from one-time accounting adjustments. Analyzing the trend of the rolling annual EPS helps identify the risk of asset overvaluation in a timely manner.

Analysis of competing companies